Monitoring of patients with acromegaly in the real-life clinical practice settings
- Authors: Ilovayskaya I.A.1, Zakharova P.A1, Metlushko E.D1
-
Affiliations:
- M.F. Vladimirsky Moscow Regional Research Clinical Institute
- Issue: Vol 29, No 11/12 (2022)
- Pages: 53-59
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/321104
- DOI: https://doi.org/10.18565/pharmateca.2022.11-12.53-59
- ID: 321104
Cite item
Abstract
Full Text
About the authors
Irena A. Ilovayskaya
M.F. Vladimirsky Moscow Regional Research Clinical Institute
Email: irena.ilov@yandex.ru
Dr. Sci. (Med.), Associate Professor, Head of the Department of Neuroendocrine Diseases, Division of the General Endocrinology Moscow, Russian Federation
P. A Zakharova
M.F. Vladimirsky Moscow Regional Research Clinical InstituteDepartment of Neuroendocrine Diseases, Division of General Endocrinology Moscow, Russian Federation
E. D Metlushko
M.F. Vladimirsky Moscow Regional Research Clinical InstituteDepartment of Neuroendocrine Diseases, Division of General Endocrinology Moscow, Russian Federation
References
- Дедов И.И, Молитвословова Н.Н., Рожинская Л.Я., Мельниченко Г.А. Федеральные клинические рекомендации по клинике, диагностике, дифференциальной диагностике и методам лечения акромегалии. Проблемы эндокринологии. 2013;59(6):4-18 doi: 10.14341/probl20135964-18.
- Dekkers O.M., Biermasz N.R., Pereira A.M., Romijn J.A., Vandenbroucke JP Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab. 2008;93(1):61-7. Doi: 10.1210. 20071191.
- Bolfi F, Neves A.F., Boguszewski C.L., Nunes-Nogueira V.S. Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis. Eur J Endocrinol. 2018;179(1):59-71. doi: 10.1530/EJE-18-0255.
- Casanueva F.F., Barkan A.L., Buchfelder M, et al; Pituitary Society, Expert Group on Pituitary Tumors. Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement. Pituitary. 2017;20(5):489-98. doi: 10.1007/s11102-017-0838-2.
- Schofl C., Franz H., Grussendorf M., et al. Participants of the German Acromegaly Register. Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German Acromegaly Register. Eur J Endocrinol. 2012;168(1):39-47. doi: 10.1530/EJE-12-0602.
- Вагапова Г.Р., Пашаев Б.Ю., Ашимова Р.Р. и др. Эффективность лечения акромегалии в республике Татарстан по данным регионального регистра опухолей гипоталамо-гипофизарной области. Альманах клинической медицины. 2021;49(4):254-60. doi: 10.18786/2072- 0505-2021-49-040
- Анциферов М.Б., Алексеева Т.М., Пронин В.С. Московский регистр больных акромегалией: отдаленные результаты наблюдения. Фарматека. 2016;16(329):62-6.
- Maione L., Chanson P. National acromegaly registries. Best Pract Res Clin Endocrinol Metab. 2019 Apr;33(2):101264. Doi: 10.1016/j. beem.2019.02.001.
- Delemer B., Chanson P., Foubert L., et al. Patients lost to follow-up in acromegaly: results of the ACROSPECT study. Eur J Endocrinol. 2014;170(5):791-97. doi: 10.1530/EJE-13-0924.
- de Jesus Nunes R., Masullo L.F., de Fonseca Lira M.Z.R., et al. Impact of the COVID-19 pandemic in the treatment of patients with acromegaly in a tertiary center: a wake-up call on the importance of telemedicine. Arch Endocrinol Metab. 2022 Jun 23:2359-3997000000491. doi: 10.20945/2359-3997000000491.
- Gatto F, Khorrami K., Nista F., et al. Acromegaly Management in a Tertiary Referral Center After 1 Year of the Coronavirus 2019 Pandemic: A Double Challenge. Endocr Pract. 2021;27(8):856-57. doi: 10.1016/j.eprac.2021.05.005.
- Анциферов М.Б., Пронин Е.В., Алексеева Т.М., Пронин В.С. Предикторы эффективности медикаментозной терапии акромегалии (по данным московского регистра). Фарматека. 2020;27(4):50-56. doi: 10.18565/pharmateca.2020.4.50-56.
- Grasso L.F, Pivonello R., Colao A. Somatostatin analogs as a first-line treatment in acromegaly: when is it appropriate? Curr Opin Endocrinol Diabetes Obes. 2012;9(4):288-94. doi: 10.1097/MED. 0b013e328354af67
- Fleseriu M., Biller B.M.K., Freda P.U., et al. A Pituitary Society update to acromegaly management guidelines. Pituitary. 2021;24(1):1-13. doi: 10.1007/s11102-020-01091-7.
- Виноградова А.В., Перфильев А.В., Триголосова И.В., Иловайская И.А. Эффективность лечения акромегалии Сандостатином ЛАР в дозах 10-40 мг. Фарматека. 2011;1:75-79.
- Иловайская И.А. Октреотид в лечении акромегалии - возможности высокодозной медикаментозной терапии. Медицинский совет. 2022;(10):148-52. doi: 10.21518/2079-701X-2022-16-10-148-152.
- Caron P.J., Bevan J.S., Petersenn S., et al; PRIMARYS Investigators Group. Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study. Pituitary. 2016;19(2):149-57. Doi: 10.1007/ s11102-015-0693-y.
- Caron P.J., Bevan J.S., Petersenn S., et al.; PRIMARYS Investigators. Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J Clin Endocrinol Metab. 2014;99(4):1282-90. doi: 10.1210/jc.2013-3318.
- Caron P.J., Bevan J.S., Petersenn S., et al.; PRIMARYS Investigators. Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J Clin Endocrinol Metab. 2014;99(4):1282-90. doi: 10.1210/jc.2013-3318.
- Neggers S.J., Pronin V., Balcere I., et al.; LEAD Study Group. Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study. Eur J Endocrinol. 2015;173(3):313-23. doi: 10.1530/EJE-15-0215.
- Salvatori R., Nachtigall L.B., Cook D.M., et al. SALSA Study Group. Effectiveness of selfor partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naive patients with acromegaly. Pituitary. 2010;13(2):115-22. Doi: 10.1007/ s11102-009-0207-x